Integrum expands its product offering to the United Kingdom market
Mölndal, Sweden – May 2, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a commercial agreement with LEDA Orthopaedics Ltd., a local medical device distributor specialized in niche trauma implants, hand surgery prostheses and unique solutions for orthopaedic procedures, to introduce OPRATM Implant System in the United Kingdom.
As part of Integrum's efforts to expand the availability of the OPRA™ Implant System to new geographical markets, the company has as of today initiated a distribution agreement in the United Kingdom with LEDA Orthopaedics (www.ledaortho.com).
“LEDA Orthopaedics are extremely proud to partner with Integrum to bring the OPRA™ Implant System to the patients and surgeons of the UK. We collaborate with some of the most innovative medical device manufacturers in the world, and we believe Integrum's game-changing products will become an important part of our portfolio,” says David Plane, Director of LEDA Orthopaedics.
“LEDA has extensive experience in providing both the NHS and independent sector clinics with specialized orthopaedics solutions, making them a great fit to represent our product portfolio. We look forward to working in close collaboration to establish our innovative products on the British market,” says Rickard Brånemark, CEO of Integrum.
For more information, please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se
Certified Adviser
Carnegie Investment Bank AB (publ).
ABOUT INTEGRUM
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.